

## *Curriculum Vitae*

### **Raymond J. Deshaies, Ph.D.**

*Caltech Division of Biology and Biological Engineering  
Howard Hughes Medical Institute*

#### **Work Address:**

HHMI/Caltech BBE, M/C 114-96  
1200 E. California Boulevard  
Pasadena, CA 91125  
Tel (626) 395-3162  
Fax (626) 395-5739  
e-mail: *deshaies@caltech.edu*

#### **Home Address:**

995 El Campo Drive  
Pasadena, CA 91107  
(626) 578 9661

**Date and Place of Birth:** September 25, 1961; Waterbury, Connecticut

#### **Education:**

1979-1983 B.S. in Biochemistry. Cornell University, Ithaca, New York  
1983-1988 Ph.D. in Biochemistry. University of California, Berkeley

#### **Positions:**

1982-1983 Undergraduate Research Assistant  
Department of Plant Physiology, Cornell University, Ithaca, NY  
1983-1988 Graduate Research Assistant (Adviser: Dr. Randy Schekman)  
Department of Biochemistry, University of California at Berkeley  
1988-1990 Postdoctoral Research Associate  
Department of Biochemistry. University of California at Berkeley  
1990-1994 Postdoctoral Research Associate (Adviser: Dr. Marc Kirschner)  
Department of Biochemistry and Biophysics, University of California at San Francisco  
1994-2000 Assistant Professor of Biology, California Institute of Technology  
2000-2005 Associate Professor of Biology, California Institute of Technology  
2000-2005 Associate Professor and Assistant Investigator  
Howard Hughes Medical Institute, California Institute of Technology  
2005-2017 Professor and Investigator  
Howard Hughes Medical Institute, California Institute of Technology  
2006-2017 Executive Officer, Division of Biology, California Institute of Technology  
2017 Senior Vice President, Discovery Research, Amgen, Inc.

**Honors and Awards:**

1979-1983	Connecticut State Scholar
1983	Graduated from Cornell University with Honors and Distinction
1984-1985	Regents Fellowship, University of California
1986-1988	NIH Graduate Assistantship
1990-1997	Lucille P. Markey Charitable Trust Scholar Award
1995-1998	Searle Scholar Award
1995	Rita Allen Foundation Scholar Award (declined)
1997-2000	Burroughs-Wellcome New Investigator Award
1997-1999	Beckman Young Investigator Award
1999	ASCB-Promega Early Career Life Scientist Award
2000	Appointed as Assistant Investigator, Howard Hughes Medical Institute
2007	Caltech Graduate Student Council Award for Teaching for 2006-2007
2007	Elected as Fellow, American Association for the Advancement of Science
2008	Biology Undergraduate Student Advisory Committee Teaching Award
2011	Elected as Member, American Academy of Arts and Sciences
2013	Appointed to Editorial Board, eLife
2016	Elected as Member, National Academy of Sciences

**Professional Activities:***Scientific Meeting Organization*

1999	Member of Program Committee for 1999 ASCB National Meeting
1999	Member of Program Committee for 2000 ASBMB National Meeting
1999	Co-Chair (with Daniel Klionsky), ASCB mini- symposium on Protein Turnover and Autophagy
2000	Chair, ASBMB symposium: ' <i>Control of cell function by regulated proteolysis</i> '
2001	Co-chair (with Judith Bond), ASBMB Satellite meeting on ' <i>Proteolysis and Cellular Regulation</i> '
2002	Co-organizer (with Jim Roberts), American Association of Cancer Research meeting on 'Ubiquitin'
2003	Co-organizer (with Peter Howley and Mark Hochstrasser), <i>The Ubiquitin Family</i> meeting, Cold Spring Harbor, April 2003
2004	Co-chair (with Avram Hershko), plenary session on <i>Proteasomes in Cancer</i> , 2004 AACR National Meeting
2005	Co-organizer (with Peter Howley and Joan Conaway), <i>The Ubiquitin Family</i> meeting, Cold Spring Harbor, April 2005
2006	Member, Education Program Committee for 2007 AACR National Meeting

- 2007 Co-organizer (with Joan Conaway and Wade Harper), *The Ubiquitin Family* meeting, Cold Spring Harbor, April 2007
- 2007 Chair, plenary session on *Ubiquitin in Cancer*, AACR National Meeting
- 2012 Co-organizer (with Ivan Dikic), Keystone Symposium, *Ubiquitin Signaling*, Whistler, British Columbia, March 2012
- 2016 Co-organizer (with Rachel Klevit), FASEB Summer Research Conference, *Ubiquitin & Cell Regulation*, Big Sky, Montana, June 2016

*Editorial*

- 1999 Member, Editorial Board, *Journal of Cell Biology*
- 1999 Co-editor (with Tyler Jacks), volume on Cell Proliferation, *Current Opinion in Cell Biology*
- 2001 Co-editor (with Martin Eilers), volume on Cell Proliferation, *Current Opinion in Cell Biology*
- 2001-2011 Founding Associate Editor, *Molecular and Cellular Proteomics*
- 2004 Member, Editorial Board, *Molecular Cell*
- 2005 Editor, *Methods in Enzymology*, Volumes 398 and 399, *Ubiquitin and Protein Degradation (Parts A and B)*
- 2012- Reviewing Editor, eLife

*Advisory and Review Panels*

- 2001 Evaluation of NIH-funded National Center for Research Resources
- 2002 Consultant, 'Proteomics Planning Meeting', NIH
- 2002-2007 Member, NIH Study Section CDF-3
- 2003-2005 Member, Defense Sciences Study Group of the Institute for Defense Analysis
- 2003 Visiting Review Committee, Institute of Molecular Biology, Academia Sinica, Taiwan
- 2006 Member, Selection Committee for ASCB Early Career Life Scientist Award
- 2006 Member, Presidential Search Committee, California Institute of Technology
- 2007 Chair, Selection Committee for ASCB Early Career Life Scientist Award
- 2009 Member, HHMI Policy Advisory Group
- 2010-2013 Member, ASCB Council
- 2010 Visiting Review Committee, King Abdul-Azziz University (Jeddah), King Abdullah University of Science and Technology (Thuwal), King Faisal University of Petroleum and Minerology (Dammam), King Saud University (Riyadh), Saudi Arabia
- 2012 Participant, NCI Industry-Academic-Government Collaborations for Cancer Target Validation Meeting
- 2015 Visiting Review Committee, King Fahd University of Petroleum and Minerology (Dammam), University of Ha'il, Princess Nora bint Abdul Rahman University (Riyadh), Saudi Arabia

*Significant Fund-raising and other Leadership Positions*

- |      |  |
|------|--|
| 2003 | Co-founder of Proteolix. Helped to raise \$18 million in venture capital in series A financing. Proteolix was acquired by Onyx in 2009.                            |
| 2006 | Founding Director, Beckman Institute Resource Center: Caltech Proteome Exploration Laboratory (CaPEL)  |
| 2006 | Awarded \$8 million by the Gordon and Betty Moore Foundation to expand the CaPEL   |
| 2011 | Co-founder of Cleave Biosciences ( <a href="http://www.cleavebio.com">www.cleavebio.com</a> ). Helped to raise \$42 million in venture capital series A financing. |

**Teaching Activities:**

- |              |   |
|--------------|---|
| 1985         | Berkeley, Spring semester. Teaching Assistant, Biochemistry Lab                                     |
| 1986         | Berkeley, Spring semester. Teaching Assistant, Biochemistry Lecture                                 |
| 1988         | Berkeley, Spring semester. Instructor, Molecular Analysis of Mitosis                                |
| 1995-present | Caltech, Spring semester. Instructor, Bi10 Undergraduate Introductory Molecular Biology Lecture/Lab |
| 1996-2002    | Caltech, Fall semester. Co-instructor, Bi226 Genetics Graduate Seminar                              |
| 1997, 1999   | Caltech, Winter semester. Instructor, Principles of Biological Analysis                             |
| 1999-2009    | Caltech, Fall semester. Instructor, Bi250 Adventures in Biology Graduate Course                     |
| 2011-present | Caltech, Spring semester. Co-instructor, Bi9 Cell Biology   |

**Technology Transfer:***Patents*

- |      |  |
|------|--|
| 2000 | U.S. Patent 6,165,731: Assay for the ubiquitination-promoting activity of human proteins       |
| 2000 | U.S. Patent 6,413,725: Biochemical assay to monitor the ubiquitin ligase activities of cullins |
| 2004 | U.S. Patent 6,713,267: Biochemical assay to monitor the ubiquitin ligase activities of cullins |
| 2005 | U.S. Patent 6,846,663: Regulation of target protein activity through modifier proteins         |
| 2006 | U.S. Patent 7,041,298 B2: Proteolysis targeting chimeric pharmaceutical                        |
| 2007 | U.S. Patent 7,208,157: Proteolysis targeting chimeric pharmaceutical                           |
| 2007 | U.S. Patent 7,279,317: Modulation of COP9 signalsome isopeptidase activity                     |
| 2007 | U.S. Patent 7,291,494: Regulation of target protein activity through modifier proteins         |
| 2008 | U.S. Patent 7,279,317: Modulation of COP9 signalsome isopeptidase activity                     |

- 2015 U.S. Patent 9,089,572: Covalent inhibitors of p97 ATPase activity
- 2015 U.S. Patent 8,865,708: Methods and compositions for inhibition of the transitional endoplasmic reticulum APTase
- 2015 U.S. Patent 7,867,724: Compositions and method of treating hypoxia-associated diseases

#### *Consulting for Commercial Entities*

- 2003-2009 Consultant, Proteolix (acquired by Onyx Pharmaceuticals in 2009)
- 2003-present Consultant, Genentech
- 2006 Appointed to Scientific Advisory Board, Rosetta Investments
- 2006 Appointed to Scientific Advisory Board, Targeted Growth Inc.
- 2006 Consultant, Chemicon-Millipore
- 2011-present Consultant and Member of Scientific Advisory Board, Cleave Biosciences

#### **Research Interests:**

*Protein Homeostasis and the Ubiquitin-Proteasome System in Health and Disease*

#### **Invited Presentations:**

- 1994 Department of Biochemistry, University of Nevada-Reno (2/94)
- 1995 Program in Genetics, UCLA (3/95)  
Invited speaker and invited discussant, Pathways Through the Cell Cycle Minisymposium, ASCB Meeting (12/95)
- 1996 Caltech Research Director's Conference (2/96)  
Invited speaker/session chair, Cold Spring Harbor Cell Cycle meeting (5/96)  
Cell Cycle Symposium, ASBMB Meeting 6/96  
Department of Biology, Purdue University (9/96)  
Graduate student seminar, Department of Pathology, Stanford 10/96  
Caltech Research Director's Conference (11/96)
- 1997 Cold Spring Harbor Yeast Genetics Course (8/97)  
Institute of Molecular Pathology, Vienna (8/97)  
Centre d'Energie Atomique, Saclay, France (10/97)  
Jacques Monod Conference on Cell Cycle, Roscoff, France (10/97)  
Swiss Federal Institute of Technology, Zurich (11/97)  
ISREC, Epalinges, Switzerland (11/97)  
Scripps Research Institute, La Jolla (11/97)  
Department of Biology, UC Santa Cruz (12/97)
- 1998 Keystone Conference on Cell Cycle (4/98)  
ProScript Inc., Cambridge MA (4/98)  
Merck Evening Lecture Series, UC Berkeley (4/98)

- Novartis, E. Hanover, NJ (4/98)  
 International Society of Nephrology Annual Meeting, Jackson WY (6/98)  
 FASEB meeting on Yeast Chromosome Metabolism, Snowmass (8/98)  
 UCLA-Harbor Medical Center (9/98)  
 Department of Biochemistry, UMDNJ (9/98)  
 Dept. of Cell Biology & Physiology, Washington Univ., St. Louis (10/98)  
 Biochemistry Program, Cal Tech (12/98)
- 1999*
- Lineberger Symposium, University of North Carolina (3/99)  
 Dept. of Biochemistry and Molecular Biology, University of Chicago (3/99)  
 Children's Hospital, Los Angeles (3/99)  
 Keystone Symposium, *Molecular Chaperones, Protein Folding, and Protein Degradation* (4/99)  
 Princeton University (5/99)  
 Graduate course in Department of Pathology, Stanford University (5/99)  
 UCLA Biochemistry Department annual retreat, Lake Arrowhead (5/99)  
 FASEB meeting on Ubiquitin (8/99)  
 NICHD Symposium on Biology of the Eukaryotic Nucleus, Berkeley Springs, WV (9/99)  
 Annual AACR meeting, San Diego (10/99)  
 University Southern California (10/99)  
 Department of Molecular Biology, UT Southwestern (11/99)  
 Department of Cell Biology, Harvard Med. (11/99)  
 Dept. of Genetics and Developmental Biology, Columbia University (11/99)
- 2000*
- Keystone Symposium, *Cancer, Cell Cycle, and Therapeutics* (1/00)  
 University of California, Irvine (1/00)  
 Annual symposium, Emory University (4/00)  
 American Society of Microbiology annual meeting, Los Angeles (5/00)  
 Symposium organizer and invited speaker, American Society of Biochemistry and Molecular Biology annual meeting, Boston (6/00)  
 Massachusetts General Hospital (6/00)  
 Molecular Genetics Gordon Conference (7/00)  
 FASEB Yeast Chromosome meeting (8/00)  
 Whitehead Symposium MIT (10/00)  
 University of California, Davis (10/00)  
 Institute of Molecular Biology, University of Oregon (11/00)  
 Biological Sciences, University of Pittsburgh (11/00)  
 Biochemistry and Biophysics, UC San Francisco (12/00)
- 2001*
- Cell Cycle Meeting, Taos (1/01)  
 Signal Pharmaceuticals (2/01)  
 GlaxoSmithKline (2/01)  
 University of Maryland Baltimore County (2/01)  
 Department of Biochemistry, St. Louis University (2/01)  
 Exelixis Pharmaceuticals (3/01)  
 MDC symposium on protein transport and stability, Berlin, (3/01)  
 ASBMB Annual Meeting, Orlando (3/01)

- Rigel Pharmaceuticals (4/01)  
 Axys Pharmaceuticals (4/01)  
 FASEB Ubiquitin meeting, Vermont (6/01)  
 Salk Institute Oncogene meeting (8/01)  
 Mass Spectrometry meeting, San Francisco (8/01)  
 Millenium Pharmaceuticals (10/01)
- 2002
- Duke University Cancer Biology Program (1/02)  
 University of Virginia, Virginia (1/01)  
 University of Colorado Health Sciences, Denver (2/02)  
 UT Health Sciences Center, San Antonio (2/02)  
 Gordon Research Conference, *Reversible Associations in Structural and Molecular Biology*, Ventura (2/02)  
 HHMI conference (3/02)  
 ABRF annual meeting Austin, Texas (3/02)  
 BSCB meeting, University of York (3/02)  
 Session chair, Cell Cycle Meeting, Cold Spring Harbor (5/02)  
 University of Utah Genetics Training Grant Retreat (5/02)  
 Proteolytic Machines in Human Disease, Bellagio, Italy (6/02)  
 FASEB Yeast Chromosome Meeting, Aspen (7/02)  
 Gordon Conference On Molecular Genetics, New London (7/02)  
 Molecular Basis of Development and Disease, Hunan, China (8/02)  
 Cytokinetics Seminar, San Francisco (9/02)  
 Genentech Inc., San Francisco (9/02)  
 Ubiquitination in Normal Cancer Cells, Vancouver, (10/02)  
*How to succeed in graduate school and beyond without really trying*, Caltech (11/02)  
*The Ubiquitin-Proteasome System*, Instituto Juan March de Estudios e Investigaciones, Madrid (11/02)  
 NCI meeting on the ubiquitin-proteasome pathway (12/02)
- 2003
- The Dana-Farber Cancer Institute, Boston (1/03)  
 Abramson Family Cancer Research Institute, Univ. of Pennsylvania (1/03)  
 Invited speaker and session chair, Keystone Symposium on Cancer Therapeutics, Banff (3/03)  
 Gordon Conference, Boston (6/03)  
 Boston Marc-a-thon, Boston (7/03)  
 ASMS meeting, Monterey (10/03)  
 Japanese Ministry of Education, Science, and Technology Symposium on Proteolysis and Cellular Regulation, Tokyo (10/03)  
 Riken Wako Institute, Saitama, Japan (10/03)  
 AACR meeting on Molecular Targets in Cancer, Boston (11/03)  
 Institute of Molecular Biology, Academia Sinica, Taiwan (12/03)
- 2004
- University of California, Los Angeles (1/04)  
 University of California, Irvine (1/04)  
 Biochemistry & Molecular Biology Seminar, Mayo Clinic, Rochester (1/04)  
 Cold Spring Harbor Laboratory (1/04)

- Memorial Sloan-Kettering Cancer Center, New York (1/04)  
 Northwestern University, Chicago (1/04)  
 AACR 95<sup>th</sup> Annual Meeting, Orlando (3/04)  
 MIT Biology Colloquium, Cambridge (3/04)  
 Distinguished Lecturer, Cornell University, Ithaca (4/04)  
 University of Washington, Seattle (4/04)  
 Pierce College, Woodland Hills, CA (4/04)  
 Washington University, St. Louis (10/04)  
 University of California, Riverside (11/04)  
 AACR *Cell Cycle and Cancer: Pathways and Therapies* conference, Ft. Lauderdale (12/04)  
 ASCB Proteolysis Symposium, Washington DC (12/04)
- 2005
- University of California, San Diego (2/05)  
 Vanderbilt University, Nashville (2/05)  
 Keystone Symposium on Ubiquitin and Signaling, Taos (2/05)  
 University of California, San Diego (3/05)  
 University of Pittsburgh (3/05)  
 Yale University (3/05)  
 AACR 96<sup>th</sup> Annual Meeting, Anaheim (4/05)  
 McGill University, Montreal (6/05)  
 Max Planck Institute for Cell Biology and Genetics, Dresden (6/05)  
 Institute of Molecular Pathology, Vienna (6/05)  
 Max Planck Institute for Developmental Biology, Tübingen (6/05)  
 Amgen, Thousand Oaks (9/05)  
 University of Colorado, Boulder (9/05)  
 City of Hope, Duarte (10/05)  
 Israel Academy of Sciences & Humanities, *Day of Ubiquitin* in honor of Nobel Prize in Ubiquitin for Avram Hershko, Aaron Ciechanover, and Irwin Rose (10/05)
- 2006
- Pomona College (1/06)  
 Plenary lecturer, KHUPO 6<sup>th</sup> Annual Meeting, Seoul (2/06)  
 Harvey Mudd College, Claremont, CA (4/06)  
 FASEB Conference, *Ubiquitin and Cellular Regulation*, Vermont Academy, Saxton's River (7/06)  
 Ubiquitin and Diseases workshop, Hebrew University, Jerusalem (10/06)  
 Keynote speaker, 5<sup>th</sup> HUPPO World Congress, Long Beach (11/06)  
 University of Wisconsin, Madison (11/06)  
 ASN 39<sup>th</sup> Annual Renal Week Meeting, San Diego (11/06)  
 University of Utah, Salt Lake City (12/06)  
 48<sup>th</sup> ASH Annual Meeting, Orlando (12/06)
- 2007
- University of San Francisco (1/07)  
 IRIC, University of Montreal (3/07)  
 17<sup>th</sup> Annual Cancer Progress Conference, New York (3/07)  
 New York University (3/07)  
 AACR Annual Meeting 2007, Los Angeles (4/07)

- The Ubiquitin Family* meeting, Cold Spring Harbor (4/07)  
 NIH/Salk Institute Workshop on Ubiquitin and Viruses (8/07)  
 2007 International Symposium on Protein Modification and Degradation,  
 Beijing (11/07)  
 University of California Los Angeles (12/07)
- 2008  
 Harvard Medical School (1/08)  
 AACR Special Conference on Ubiquitin and Cancer, San Diego (1/08)  
 University of Southern California (3/08)  
 FASEB conference, *Ubiquitin & Cellular Regulation*, Saxton's River (6/08)  
 Watson Lecture, Caltech (11/08)
- 2009  
 Keystone Symposium, Copper Mountain, Colorado (1/09)  
 Harvard Center for Cancer Biology Symposium (2/09)  
 FASEB Experimental Biology 2009, New Orleans (4/09)  
*The Ubiquitin Family* meeting, Cold Spring Harbor (4/09)  
 University of California, San Diego (5/09)  
*Cell Signaling and Molecular Dynamics* Symposium, Cornell (10/09)
- 2010  
 Burnham Institute, San Diego (2/10)  
 Weill Cornell Medical College, New York (3/10)  
 University of Kentucky, Lexington (3/10)  
*Proteomics of Protein Degradation & Ubiquitin Pathways*, Vancouver (6/10)  
 FASEB *Ubiquitin and Cellular Regulation* conference, Saxton's River (6/10)  
 Genomics Institute of the Novartis Foundation, San Diego (8/10)  
 FASEB conference, *Yeast Chromosome Structure, Replication & Segregation*, Carefree (8/10)  
 Scottish Institute for Cell Signaling (SCILLS), Edinburgh (8/10)  
 Research Institute of Molecular Pathology (IMP), Vienna (9/10)  
 University of California, Irvine (9/10)  
 University of California, Santa Cruz (10/10)  
*Signaling Through Ubiquitin* meeting, Cold Spring Harbor (11/10)
- 2011  
 University of California, Berkeley (1/11)  
 New York University (2/11)  
 Princeton University (2/11)  
 Keystone Symposium, *AAA and Related ATP-driven Protein Machines*,  
 Tahoe City, CA (3/11)  
*The Ubiquitin Family* meeting, Cold Spring Harbor (5/11)  
 The 26<sup>th</sup> Aspen Cancer Conference, Aspen, CO (7/11)  
 Institute of Biochemistry, Goethe University, Frankfurt (9/11)  
 EMBO Conference, *Ubiquitin and Ubiquitin-Like Modifiers*, Cavtat (9/11)  
 ASCB Annual Meeting, Denver (12/11)
- 2012  
 Harvard Medical School (1/12)  
 The Scripps Research Institute (2/12)  
 Keystone Symposium, *NF-kappaB Signaling and Biology: From bench to bedside/Ubiquitin signaling*, Whistler, British Columbia (3/12)

- Pepperdine University (3/12)  
FASEB *Ubiquitin & Cellular Regulation* conference, Saxtons River (6/12)  
Max-Delbrück-Center for Molecular Medicine, Berlin (9/12)  
XOMES VII, *Ubiquitin family proteins and their cognate PCI complexes*,  
Munich (9/12)  
ETH Zurich Institute of Biochemistry (9/12)  
ComBio 2012, Adelaide (9/12)
- 2013  
University of California, Los Angeles (2/13)  
3<sup>rd</sup> Ubiquitin Research and Drug Discovery Conference, Las Vegas (2/13)  
University of South Dakota, Vermillion (4/13)  
*The Ubiquitin Family* meeting, Cold Spring Harbor (5/13)  
Temple University (5/13)  
University of Pennsylvania (5/13)  
Proteasome-Ubiquitin Minisymposium, Tokyo (7/13)  
Naito Conference, Sapporo (7/13)  
EMBO Workshop, *AAA+ Proteins*, Neuss (9/13)  
The 5<sup>th</sup> EMBO Meeting, Amsterdam (9/13)
- 2014  
Keynote speaker, Keystone Symposium, Big Sky (1/14)  
University of Texas Southwestern Medical Center (2/14)  
ASBMB Annual Meeting, San Diego (4/14)  
FASEB conference, *Ubiquitin & Cellular Regulation*, Saxtons River (6/14)  
60<sup>th</sup> Benzon Symposium, Copenhagen (8/14)  
3<sup>rd</sup> Annual ICBS Conference, San Francisco (11/14)  
ZOMES VII Conference, Xiamen (11/14)  
HKUST Strategic Partnership Workshop, Hong Kong (12/14)
- 2015  
University of Wisconsin, Madison (1/15)  
University of Nevada, Las Vegas (2/15)  
5<sup>th</sup> Ubiquitin Research and Drug Discovery Conference, San Diego (2/15)  
US Human Proteome Organization Annual Meeting, Tempe (3/15)  
Stanford School of Medicine (3/15)  
Partners in Discovery: Caltech-City of Hope Biomedical Research Initiative  
Workshop (4/15)  
Pfizer 8<sup>th</sup> Annual Frontiers in Human Disease Symposium, New York (4/15)  
University of California, San Diego (6/15)  
Leiden University Medical Center (9/15)  
EMBO Conference, *Ubiquitin and ubiquitin-like modifiers*, Cavtat (9/15)  
ZMBH, Heidelberg (9/15)  
Institute of Molecular Biology, Mainz (9/15)  
*Cell Biology of Yeasts* meeting, Cold Spring Harbor (11/15)  
ENMC VCP *Multisystem Proteinopathy* workshop, Naarden (11/15)

- 2016            University of Kansas Cancer Center (1/16)  
                  City of Hope, Duarte (1/16)  
                  Keynote speaker, 6<sup>th</sup> Ubiquitin Research & Drug Discovery Conference, San  
                  Diego (2/16)  
                  Keystone Symposium, *Ubiquitin Signaling*, Whistler, BC (3/16)  
                  Keynote speaker, Experimental Biology 2016, San Diego (4/16)  
                  University of California, Berkeley (4/16)  
                  Yale (9/16)  
                  Protein Signaling Conference, Copenhagen (10/16)  
                  Ecole Polytechnique Federale de Lausanne (11/16)  
                  University of California, San Francisco (11/16)
- 2017            Children's Hospital of Philadelphia (1/17)

**Research Support:**

- Howard Hughes Medical Institute Assistant Investigator Award  
Period: 7/01/00 to 8/31/20  
Title: *Control of Cell Proliferation by Ubiquitin-Dependent Proteolysis*
- R01 GM065997  
Period: 5/1/11 to 4/30/19  
Title: *Regulation of cullin-RING ligases by Nedd8*
- R01 CA164803  
Period: 1/01/13 to 12/31/17  
Title: *Role of CSN5 in the activity and dynamic cycling of cullin-RING  
ubiquitin ligases*
- Gates/Grubstake Fund Award  
Period: 10/1/13 to 9/30/19  
Title: *Using IMiDs as a versatile platform to control protein degradation*
- NIH  
Period: 09/01/15 to 08/31/20  
Title: Nanosystems Biology Cancer Center

## BIBLIOGRAPHY

1. Fish, L.E., Deshaies, R., and Jagendorf, A.T. (1983). A  $Mg^{2+}$  requirement for rapid ATP-driven protein synthesis by intact pea chloroplasts. *Plant Sci. Lett.* 31, 139-146.
2. Deshaies, R.J., Fish, L.E., and Jagendorf, A.T. (1984). Permeability of chloroplast envelopes to  $Mg^{2+}$ . Effects on protein synthesis. *Plant Physiol.* 74, 956-961.
3. Deshaies, R.J., and Schekman, R. (1987). A yeast mutant defective at an early stage in import of secretory protein precursors into the endoplasmic reticulum. *J. Cell Biol.* 105, 633-645.
4. Deshaies, R.J., Koch, B.D., Werner-Washburne, M., Craig, E.A., and Schekman, R. (1988). A subfamily of stress proteins facilitates translocation of secretory and mitochondrial precursor polypeptides. *Nature* **332**, 800-805.
5. Bohni, P.C., Deshaies, R.J., and Schekman, R. (1988). *SEC11* is required for signal peptide processing and yeast cell growth. *J. Cell Biol.* 106, 1035-1042.
6. Deshaies, R.J., Koch, B.D., and Schekman, R. (1988). The role of stress proteins in membrane biogenesis. *Trends Biochem. Sci.* 13, 384-388.
7. Deshaies, R.J., Kepes, F., and Bohni, P.C. (1989). Genetic dissection of the early stages of protein secretion in yeast. *Trends Genet.* 5, 87-93.
8. Deshaies, R.J., and Schekman, R. (1989). *SEC62* encodes a putative membrane protein required for protein translocation into the yeast endoplasmic reticulum. *J. Cell Biol.* 109, 2653-2664.
9. Rothblatt, J.A., Deshaies, R.J., Sanders, S.L., Daum, G., and Schekman, R. (1989). Multiple genes are required for proper insertion of secretory proteins into the endoplasmic reticulum in yeast. *J. Cell Biol.* 109, 2641-2652.
10. Deshaies, R.J. and Schekman, R. (1990). Structural and functional dissection of Sec62p, a membrane-bound component of the yeast endoplasmic reticulum protein import machinery. *Mol. Cell. Biol.* 10, 6024-6035.
11. Deshaies, R.J., Sanders, S., Feldheim, D., and Schekman, R. (1991). Assembly of yeast Sec proteins involved in translocation into the endoplasmic reticulum into a membrane-bound multisubunit complex. *Nature* 349, 806-808.
12. Stirling, C.J., Rothblatt, J., Hosobuchi, M., Deshaies, R., and Schekman, R. (1992). Protein translocation mutants defective in the insertion of integral membrane proteins into the endoplasmic reticulum. *Mol. Biol. Cell* 3, 129-142.
13. Esnault, Y., Blondel, M.O., Deshaies, R.J., Schekman, R. and Kepes, F. (1993). The yeast *SSS1* gene is essential for secretory protein translocation and encodes a conserved protein of the endoplasmic reticulum. *EMBO J.* 12, 4083-4093.
14. Booher, R.N., Deshaies, R.J. and Kirschner, M.W. (1993). Properties of *Saccharomyces cerevisiae* *wee1* and its differential regulation of p34<sup>CDC28</sup> in response to G1 and G2 cyclins. *EMBO J.* 12, 3417-3426.
15. Li, J.J. and Deshaies, R. J. (1993). Exercising self-restraint: discouraging illicit acts of S and M in eukaryotes. *Cell* 74, 223-226.

16. Deshaies, R.J., Chau, V., and Kirschner, M.W. (1995). Ubiquitination of the G1 cyclin Cln2p by a Cdc34p-dependent pathway. *EMBO J.* 14, 303-312.
17. Deshaies, R.J. and Kirschner, M.W. (1995). G1 cyclin-dependent activation of p34<sup>CDC28</sup> *in vitro*. *Proc. Natl. Acad. Sci. USA* 92, 1182-1186.
18. Gerber, M.R., Farrell, A., Deshaies, R.J., Herskowitz, I. and Morgan, D.O. (1995). CDC37 is required for association of the protein kinase CDC28 with G1 and mitotic cyclins. *Proc. Natl. Acad. Sci. USA* 92, 4651-4655.
19. Banerjee, A., Deshaies, R.J., and Chau, V. (1995). Characterization of a dominant negative mutant of the cell cycle ubiquitin-conjugating enzyme Cdc34. *J. Biol. Chem.* 270, 26209-26215.
20. Deshaies, R.J. (1995). Make it or break it: the role of ubiquitin-dependent proteolysis in cellular regulation. *Trends Cell Bio.* 5, 428-434.
21. Deshaies, R.J. (1995). The self-destructive personality of a cell cycle in transition. *Curr. Opin. Cell Biol.* 7, 781-789.
22. King, R.W., Deshaies, R.J., Peters, J.M., and Kirschner, M.W. (1996). How proteolysis drives the cell cycle. *Science* 274, 1652-1659.
23. Deshaies, R.J. (1997). Phosphorylation and proteolysis: partners in the regulation of cell division in budding yeast. *Curr. Opin. Genet. Dev. Biol.* 7, 7-16.
24. Verma, R., Chi, Y., and Deshaies, R.J. (1997). Cell-free ubiquitination of cell cycle regulators in budding yeast extracts. *Methods Enzymol.* 283, 366-376.
25. Verma, R., Feldman, R.M.R., and Deshaies, R. J. (1997). SIC1 is ubiquitinated *in vitro* by a pathway that requires CDC4, CDC34, and cyclin/CDK activities. *Mol. Biol. Cell* 8, 1427-1437.
26. Verma, R., Annan, R., Huddleston, M., Carr, S., Reynard, G., and Deshaies, R.J. (1997). Phosphorylation of Sic1p by G1 cyclin/Cdk is required for its degradation and entry into S phase. *Science* 278, 455-460.
27. Feldman, R.M.R., Correll, C.C., Kaplan, K.B., and Deshaies, R.J. (1997). A Complex of Cdc4, Skp1, and Cdc53/Cullin Catalyzes Ubiquitination of the Phosphorylated CDK Inhibitor Sic1. *Cell* 91, 221-230.
28. Henchoz, S., Chi, Y., Catarin, B., Herskowitz, I., Deshaies, R.J., and Peter, M. (1997). Phosphorylation and ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor Far1p in budding yeast. *Genes Dev.* 11, 3046-3060.
29. Lyapina, S.L., Correll, C.C., Kipreos, E.T., and Deshaies, R.J. (1998). Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. *Proc. Natl. Acad. Sci. USA* 95, 7451-7456.
30. Peters, J.-M., King, R.W., and Deshaies, R.J. (1998). Cell cycle control by ubiquitin-dependent proteolysis. In *Ubiquitin and the Biology of the Cell* (Ed. J.-M. Peters et al.) Plenum Press, NY.

31. Shou, W., Seol, J.H., Shevchenko, A., Baskerville, C., Moazed, D., Chen, Z.W.S., Jang, J., Shevchenko, A., Charbonneau, H., and Deshaies, R.J. (1999). Exit from mitosis triggered by Tem1-dependent release of the protein phosphatase Cdc14 from nucleolar RENT complex. *Cell* 97, 233-244.
32. Deshaies R.J., and Jacks T. (1999). Cell multiplication peering in and peering out: regulation of and by the cell cycle. *Curr. Opin. Cell Biol.* 11, 705-707.
33. Straight, A.F., Shou, W., Dowd, G.J., Turck, C.W., Deshaies, R.J., Johnson, A.D., and Moazed, D. (1999). Net1, a Sir2-associated nucleolar protein required for rDNA silencing and nucleolar integrity. *Cell* 97, 245-256.
34. Seol, J.H., Feldman, R.M.R., Zachariae, W., Shevchenko, A., Correll, C.C., Lyapina, S., Chi, Y., Galova, M., Claypool, J., Sandmeyer, S., Nasmyth, K., Shevchenko, A., and Deshaies, R.J. (1999). Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. *Genes Dev.* 13, 1614-1626.
35. Freed, E., Lacey, K.R., Huie, P., Lyapina, S.A., Deshaies, R.J., Stearns, T., and Jackson, P.K. (1999). Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle. *Genes Dev.* 13, 2242-2257.
36. Deshaies, R.J. (1999). SCF and cullin/RING H2-based ubiquitin ligases. *Annu. Rev. Cell Dev. Biol.* 15, 435-467.
37. Verma, R., and Deshaies, R.J. (2000). A proteasome *howdunit*: the case of the missing signal. *Cell* 101, 341-344.
38. Deshaies, R.J., and Meyerowitz, E.M. (2000). COP1 patrols the night beat. *Nat. Cell Biol.* 2, E102-E104.
39. Reynard, G.J., Reynolds, W., Verma, R., and Deshaies, R.J. (2000). CKS1 is required for G1 cyclin/CDK activity in budding yeast. *Mol. Cell Biol.* 20, 5858-5864.
40. Verma, R., Chen, S., Feldman, R., Schieltz, D., Yates, J., and Deshaies, R.J. (2000). Proteasomal proteomics: identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes. *Mol. Biol. Cell* 11, 3425-39.
41. Blondel, M., Galan, J.M., Chi, Y., Lafourcade, C., Longaretti, C., Deshaies, R.J., and Peter, M. (2000). Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. *EMBO J.* 19, 6085-6097.
42. Annan, R.S, Huddleston, M.J., Verma, R., Deshaies, R.J., and Carr, S.A. (2001). A multidimensional electrospray MS-based approach to phosphopeptide mapping. *Anal. Chem.* 73, 393-404.
43. Lippincott J., Shannon K.B., Shou W., Deshaies R.J., Li R. (2001). The Tem1 small GTPase controls actomyosin and septin dynamics during cytokinesis. *J. Cell Sci.* 7, 1379-86.
44. Traverso, E.E., Baskerville, C., Liu, Y., Shou, W., James, P., Deshaies, R.J., Charbonneau, H. (2001). Characterization of the net1 cell cycle-dependent regulator of the Cdc14 phosphatase from budding yeast. *J. Biol. Chem.* 276, 21924-31.

45. Seol, J.H., Shevchenko, A., Shevchenko, A., and Deshaies, R.J. (2001). Skp1 forms multiple protein complexes, including RAVE, a regulator of V-ATPase assembly. *Nat. Cell Biol.* **4**, 384-91.
46. Galan, J.-M., Wiederkehr, A., Seol, J.H., Deshaies, R.J., Riezman, H., and Peter, M. (2001). Skp1p and the F-box protein Rcy1p form a non-SCF complex involved in recycling of the SNARE Snc1p in yeast. *Mol. Cell Biol.* **9**, 3105-17.
47. Chi, Y., Huddleston, M.J., Zhang, X., Young, R.A., Annan, R.S., Carr, S.A., and Deshaies, R.J. (2001). Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. *Genes Dev.* **9**, 1078-92.
48. Schwechheimer, C., Serino, G., Callis, J., Crosby, W.L., Lyapina, S., Deshaies, R.J., Gray W.M. Estelle M., Deng, X.W. (2001). Interactions of the COP9 signalosome with the E3 ubiquitin ligase SCFTIR1 in mediating auxin response. *Science* **18**, 1379-82.
49. Lyapina, S., Cope, G., Shevchenko, A., Serino, G., Tsuge, T., Zhou, C., Wolf, D.A., Wei, N., Shevchenko, A., and Deshaies, R.J. (2001). Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. *Science* **18**, 1382-5.
50. Mah, A.S., Jang, J., and Deshaies, R.J. (2001). Protein kinase Cdc15 activates the Dbf2-Mob1 kinase complex. *Proc. Natl. Acad. Sci. USA* **13**, 7325-30.
51. Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.C., and Deshaies, R.J. (2001). Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. *Proc. Natl. Acad. Sci. USA* **98**, 8554-9.
52. Zhou, C., Seibert, V., Geyer, R., Rhee, E., Lyapina, S., Cope, Greg., Deshaies R.J., Wolf, D.A. (2001). The fission yeast COP9/ signalosome is involved in cullin modification by ubiquitin-related Ned8p. *BMC Biochem.* **2**, 7.
53. Shou, W., Sakamoto, K.M., Keener, J., Morimoto, K.W., Traverso, E., Azzam, R., Hoppe, G.J., Feldman, R.M., DeModena, J., Moazed, D., Charbonneau, H., Nomura, M., and Deshaies, R.J. (2001). Net1 stimulates RNA polymerase I transcription and regulates nucleolar structure independently of controlling mitotic exit. *Mol. Cell* **8**, 45-55.
54. Verma, R., McDonald, W.H., Yates, J.R. III, and Deshaies, R.J. (2001). Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields fully active S phase cyclin-Cdk. *Mol. Cell* **8**, 439-48.
55. Wu, G., Lyapina, S., Das, I., Li, J., Guerny, M., Chui, I., Deshaies R.J., and Kitajewski, J. (2001). SEL-10, a negative regulator of notch signaling, targets notch for ubiquitin-mediated protein degradation. *Mol. Cell Biol.* **21**, 7403-15.
56. Deshaies, R.J., and Eilers, M. (2001). Editorial Review: Cell Multiplication. *Curr. Opin. Cell Biol.* **13**, 729-730.
57. Deshaies, R.J. and Ferrell, J.E. (2001). Multisite phosphorylation and the countdown to S phase. *Cell* **107**, 819-822.
58. Deshaies, R.J., Seol, J.H., McDonald, W.H., Cope, G., Lyapina, S., Shevchenko, A., Shevchenko A., Verma, R., and Yates, J.R. (2002). Charting the protein complexome in yeast by mass spectrometry. *Mol. Cell. Prot.* **1**, 3-10.

59. Shou, W., and Deshaies, R.J. (2002). Multiple telophase arrest bypassed (tab) mutants alleviate the essential requirement for Cdc15 in exit from mitosis in *S. cerevisiae*. *BMC Genet.* 3, 4.
60. Shou, W., Azzam, R., Chen, S.L., Huddleston, M.J., Baskerville, C., Charbonneau, H., Annan, R.S., Carr, S.A., and Deshaies, R.J. (2002). Cdc5 influences phosphorylation of Net1 and disassembly of the RENT complex. *BMC Mol. Biol.* 3, 3.
61. Shou, W., Verma, R., Annan, R.S., Huddleston, M.J., Chen, S.L., and Deshaies R.J. (2002). Mapping phosphorylation sites in proteins by mass spectrometry. *Method. Enzymol.* 351, 279-296.
62. Loughrey Chen S., Huddleston, M.J., Shou, W., Deshaies, R.J., Annan, R.S., and Carr, S.A. (2002). Mass spectrometry-based methods for phosphorylation site mapping of hyperphosphorylated proteins applied to Net1, a regulator of exit from mitosis in yeast. *Mol. Cell. Prot.* 1, 186-96.
63. Verma, R., Aravind L., Oania, R., McDonald, W.H., Yates, J. R. III, Koonin, E.V. and Deshaies, R.J. (2002). Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. *Science* 298, 611-615.
64. Cope, G.A., Suh, G.S., Aravind, L., Schwarz, S.E., Zipursky, S.L., Koonin, E.V. and Deshaies, R.J. (2002). Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of NEDD8 from CUL1. *Science* 298, 608-611.
65. Park C.J., Song, S., Lee P.R., Shou W., Deshaies R.J. and Lee K.S (2003). Loss of CDC5 function in *saccharomyces cerevisiae* leads to defects in Swe1p regulation and Bfa1p/Bub2p-independent cytokinesis. *Genetics* 163, 21-33.
66. Petroski, M.D, and Deshaies, R.J. (2003). Context of multiubiquitin chain attachment influences the rate of Sic1 degradation. *Mol. Cell* 11, 1435-44.
67. Petroski, M.D, and Deshaies, R.J. (2003). Redundant degrons ensure the rapid destruction of sic1 at the g1 /s transition of the budding yeast cell cycle. *Cell Cycle* 2, 410-1.
68. Cope, G.A., and Deshaies, R.J. (2003). COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. *Cell* 114, 663-71.
69. Lipford, J.R., and Deshaies, R.J. (2003). Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. *Nat. Cell Biol.* 5, 845-50.
70. Sakamoto, K.M., Kim, K.B., Verma, R., Ransick, A., Stein, B., Crews, C.M., and Deshaies, R.J. (2003). Development of PROTACS to target cancer-promoting proteins for ubiquitination and degradation. *Mol. Cell. Proteomics* 2, 1350-1358.
71. Ambroggio, X.I., Rees, D.C., and Deshaies, R.J. (2004). JAMM: A metalloprotease-like zinc site in the proteasome and signalosome. *PLoS Biol.* 2, 0113-0119.
72. Baumeister, W., Bachmair, A., Chau, B., Cohen, R., Coffino, P., DeMartino, G., Deshaies, R., et al. (2004). Varshavsky's Contributions (in Letters). *Science* 19, 1290-1292.
73. Graumann, J., Dunipace, L.A., Seol, J.H., McDonald, W.H., Yates, J.R. III, Wold, B.J., and Deshaies, R.J. (2004). Applicability of TAP-MudPIT to pathway proteomics in yeast. *Mol. Cell. Proteomics* 3, 266-237.

74. Schneekloth, J.S. Jr., Fonseca, F.N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., and Crews, C.M. (2004). Chemical genetic control of protein levels: selective in vivo targeted degradation. *J. Am. Chem. Soc.* 126, 3748-3754.
75. Wertz, I.E., O'Rourke, K.M., Zhang, Z., Dornan, D., Arnott, D., Deshaies, R.J., and Dixit, V.M. (2004). Human De-etiololed-1 regulates cJun by assembling a CUL 4A ubiquitin ligase. *Science* 303, 1371-1374.
76. Verma, R., Oania, R., Graumann, J., and Deshaies, R.J. (2004). Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. *Cell* 118, 99-110.
77. Azzam, R., Chen, S.L., Shou, W., Mah, A.S., Alexandru, G., Nasmyth, K., Annan, R.S., Carr, S.A., and Deshaies, R.J. (2004). Phosphorylation by cyclin B-Cdk underlies release of mitotic exit. *Science* 305, 516-519.
78. Verma, R., Peters, N.R., Tochtrop, G.P., Sakamoto, K.M., D'Onofrio, M., Varadan, R., Fushman, D., Deshaies, R.J., and King, R.W. (2004). Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. *Science* 306, 117-120.
79. Petroski, M.D. and Deshaies, R. J. (2005). Function and regulation of cullin-RING ubiquitin ligases. *Nat. Rev. Mol. Cell. Biol.* 6, 9-20.
80. Mayor, T., Lipford, J.R., Graumann, J., Smith G.T., and Deshaies, R.J. (2005). Analysis of poly-ubiquitin conjugates reveals that the Rpn10 substrate receptor contributes to the turnover of multiple proteasome targets. *Mol. Cell. Proteomics* 4, 741-751.
81. Lipford, J.R., Smith, G.T., Chi, Y., and Deshaies, R.J. (2005). A putative stimulatory role for activator turnover in gene expression. *Nature* 438, 113-116.
82. Mah, A.S., Elia, A.E.H., Devgan, G, Ptacek, J., Schutkowski, M., Snyder, M., Yaffe, M.B., and Deshaies, R.J. (2005). Substrate specificity analysis of protein kinase complex Dbf20Mob1 by peptide library and proteome array screening. *BMC Biochem.* 6, 22.
83. Mayor, T. and Deshaies, R.J. (2005). Two-step affinity purification of multiubiquitylated proteins from *Saccharomyces cerevisiae*. *Method. Enzymol.* 399, 385-392.
84. Verma, R. and Deshaies, R.J. (2005). Assaying degradation and deubiquitination of a ubiquitinated substrate by purified 26S proteasomes. *Method. Enzymol.* 398, 391-399.
85. Petroski, M.D. and Deshaies, R.J. (2005). In vitro reconstitution of SCF substrate ubiquitination with purified proteins. *Method. Enzymol.* 398, 143-158.
86. Petroski, M.D. and Deshaies, R.J. (2005). Mechanism of lysine 48-linked ubiquitin-chain synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. *Cell* 123, 1107-1120.
87. Cope, G.A. and Deshaies, R.J. (2006). Targeted silencing of Jab1 /Csn5 in human cells downregulates SCF activity through reduction of F-box protein levels. *BMC Biochem.* 7, 1.
88. Sharon, M., Taverner, T., Ambroggio, X.I., Deshaies, R.J., and Robinson, C.V. (2006). Structural organization of the 19% proteasome lid: Insights from MS of intact complexes. *PLoS Biol.* 4, 1314-1323 (e267).

89. Petroski, M.D., Kleiger, G., and Deshaies, R.J. (2006). Evaluation of a diffusion-driven mechanism for substrate ubiquitination by the SCF-Cdc34 ubiquitin ligase complex. *Mol Cell* 24, 523-534.
90. Ghaboosi, N. and Deshaies, R.J. (2007). A conditional yeast E1 mutant blocks the ubiquitin-proteasome pathway and reveals a role for ubiquitin conjugates in targeting Rad23 to the proteasome. *Mol. Biol. Cell* 18, 1953-63.
91. Mayor, T., Graumann, J., Bryan, J., Maccoss, M.J., and Deshaies, R.J. (2007). Quantitative profiling of ubiquitylated proteins reveals proteasome substrates and the substrate repertoire influenced by the Rpn10 receptor pathway. *Mol. Cell. Proteomics* 6, 1885-1895.
92. Haririnia, A., Verma, R., Purohit, N., Twarog, M.Z., Deshaies, R.J., Bolon, D., and Fushman, D. (2008). Mutations in the hydrophobic core of ubiquitin differentially affect its recognition by receptor proteins. *J. Mol. Biol.* 375, 979-996.
93. Goh, A.M., Walters, J.K., Elsasser, S., Verma, R., Deshaies, R.J., Finley, D., and Howley, P.M. (2008). Components of the ubiquitin-proteasome pathway compete for surfaces on Rad32 family proteins. *BMC Biochem.* 9, 4.
94. Alexandru, G., Graumann, J., Smith, G.T., Kolawa, N.J., Fang, R., and Deshaies, R.J. (2008). UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1a turnover. *Cell* 134, 804-816.
95. Saha, A. and Deshaies, R. J. (2008). Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. *Mol. Cell* 32, 21-31.
96. Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C.M., Deshaies, R.J., and Sakamoto, K.M. (2008). Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. *Oncogene* 27, 7201-7211.
97. Collins, G.A., Lipford, J.R., Deshaies, R.J., Tansey, W.P. (2009). Gal4 turnover and transcription activation (Brief Communication Arising). *Nature* 461, (8 October) E7.
98. Mohl, D.A., Huddleston, M.J., Collingwood, T.S., Annan, R.S., and Deshaies, R.J. (2009). Dbf2-Mob1 drives relocalization of protein phosphatase Cdc14 to the cytoplasm during exit from mitosis. *J. Cell Biol.* 184, 527-539.
99. Machida, K., Tsukamoto, H., Mkrtychyan, H., Duan, L., Dynnyk, A., Liu, H.M., Asahina, K., Govindarajan, S., Ray, R., Ou, J.H., Seki, E., Deshaies, R., Miyake, K., and Lai, M.M. (2009). Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. *Proc. Nat. Acad. Sci. USA* 106, 1548-1553.
100. Oh, Y.M., Kwon, Y.E., Kim, J.M., Bae, S.J., Lee, B.K., Yoo, S.J., Chung, C.H., Deshaies R.J., Seol, J.H. (2009) Chfr is linked to tumour metastasis through the downregulation of HDAC1. *Nat. Cell Biol.* 11, 295-302.
101. Deshaies, R.J. (2009). Drug discovery: Fresh target for cancer therapy (News & Views). *Nature* 458, 709-710.
102. Deshaies, R.J. and Joazeiro, C.A.P. (2009). RING domain E3 ubiquitin ligases. *Annu. Rev. Biochem.* 78, 399-434.

103. Kleiger, G., Hao, B., Mohl, D.A., and Deshaies, R.J. (2009). The acidic tail of the Cdc34 ubiquitin-conjugating enzyme functions in both binding to and catalysis with ubiquitin ligase SCF<sup>CDC4</sup>. *J. Biol. Chem.* 284, 36012-36023.
104. Kleiger, G., Saha, A., Lewis, S., Kuhlman, B., and Deshaies, R.J. (2009). Rapid E2-E3 assembly and disassembly enable processive ubiquitylation of cullin-RING ubiquitin ligase substrates. *Cell* 139, 957-968.
105. Pierce, N., Kleiger, G., Shan, S., and Deshaies, R.J. (2009). Detection of sequential ubiquitination on a millisecond time-scale. *Nature* 462, 615-619.
106. Radhakrishnan, S.K., Lee, C.S., Young, P., Beskow, A, Chan, J.Y., and Deshaies, R.J. (2010). Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. *Mol. Cell* 38, 17-28.
107. Aghajan, M., Jonai, N., Flick, K., Fu, F., Luo, M., Cai, X., Ouni, I., Pierce, N., Tang, X., Lomenick, B., Damoiseaux, R., Hao, R., Del Moral, P.M., Verma, R., Li, Y., Li, C., Houk, K.N., Jung, M.E., Zheng, N., Huang, L., Deshaies, R.J., Kaiser, P., and Huang, J. (2010). Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. *Nat. Biotechnol.* 28, 738-742.
108. Collins, G.A., Gomez, T.A., Deshaies, R.J., and Tansey, W.P. (2010). Combined chemical and genetic approach to inhibit proteolysis by the proteasome. *Yeast* 27, 965-974.
109. Tyrell, A., Flick, K., Kleiger, G., Zhang, H., Deshaies, R.J., and Kaiser, P. (2010). Physiologically relevant and portable tandem ubiquitin-binding domain stabilizes polyubiquitylated proteins. *Proc. Natl. Acad. Sci. USA* 107, 19796-19801.
110. Deshaies, R.J., Emberley, E.D., and Saha, A. (2010). Control of cullin-ring ubiquitin ligase activity by Nedd8. *Subcell. Biochem.* 54, 41-56.
111. Verma, R., Oania, R., Fang, R., Smith, G.T., and Deshaies, R.J. (2011). Cdc48/p97 mediates UV-dependent turnover of RNA Pol II. *Mol. Cell* 41, 82-92.
112. Chou, T.F., Brown, S.J., Minond, D., Nordin, B.E., Li, K., Jones, A.C., Chase, P., Porubsky, P.R., Stoltz, B.M., Schoenen, F.J., Patricelli, M.P., Hodder, P., Rosen, H., and Deshaies, R.J. (2011) Reversible inhibitor of p97, DBE-Q, impairs both ubiquitin-dependent and autophagic protein clearance pathways. *Proc. Natl. Acad. Sci. USA* 108, 4834-4839.
113. Saha, A., Lewis, S., Kleiger, G., Kuhlman, B., and Deshaies, R.J. (2011). Essential role for ubiquitin-ubiquitin-conjugating enzyme interaction in ubiquitin discharge from Cdc34 to substrate. *Mol. Cell* 42, 75-83.
114. Lee, J.E., Sweredoski, M.J., Graham, R.L., Kolawa, N.J., Smith, G.T., Hess, S., and Deshaies, R.J. (2011). The steady-state repertoire of human SCF Ubiquitin ligase complexes does not require ongoing Nedd8 conjugation. *Mol. Cell. Proteomics* 10, 6460 1-9.
115. Chou, T.F. and Deshaies, R.J. (2011). Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. *J. Biol. Chem.* 286, 16546-16554.
116. Chou, T.F. and Deshaies, R.J. (2011). Development of p97 AAA ATPase inhibitors. *Autophagy* 7, 1091-1092.

117. Gomez, T.A., Kolawa, N., Gee, M., Sweredoski, M.J., and Deshaies, R.J. (2011) Identification of a functional docking site in the Rpn1 LRR domain for the UBA-UBL domain protein Ddi1. *BMC Biol.* 9, 33.
118. Rabut, G., Le Dez, G., Verma, R., Makhnevych, T., Knebel, A., Kurz, T., Boone, C., Deshaies, R.J. and Peter, M. (2011). The TFIIF subunit Tfb3 regulates cullin neddylation. *Mol. Cell.* 43, 488-495.
119. Sohn, C.H., Lee, J.E., Sweredoski, M.J., Graham, R.L., Smith, G.T., Hess, S., Czerwieniec, G., Loo, J.A., Deshaies, R.J., Beauchamp, J.L. (2012). Click chemistry facilitates formation of reporter ions and simplified synthesis of amine-reactive multiplexed isobaric tags for protein quantification. *J. Am. Chem. Soc.* 134, 2672-2680.
120. Haines, D.S., Lee, J.E., Beauparlant, S.L., Kyle, D.B., den Besten, W., Sweredoski, M.J., Graham, R.L., Hess, S., and Deshaies, R.J. (2012). Protein interaction profiling of the p97 adaptor UBXD1 points to a role for the complex in modulating ERGIC-53 trafficking. *Mol. Cell. Proteomics* 11, M111.016444.
121. Sohn, C.H., Agnew, H.D., Lee, J.E., Sweredoski, M.J., Graham, R.L., Smith, G.T., Hess, S., Czerwieniec, G., Loo, J.A., Heath, J.R., Deshaies, R.J., and Beauchamp, J.L. (2012). Designer reagents for mass spectrometry-based proteomics: clickable cross-linkers for elucidation of protein structures and interactions. *Anal. Chem.* 84, 2662-2669.
122. Besten, W.D., Verma, R., Kleiger, G., Oania, R.S., and Deshaies, R.J. (2012). NEDD8 links cullin-RING ubiquitin ligase function to the p97 pathway. *Nat. Struct. Mol. Biol.* 19, 511-516.
123. Emberley, E.D., Mosadeghi, R., and Deshaies, R.J. (2012). Deconjugation of Nedd8 from Cull1 is directly regulated by Skp1-Fbox and substrate, and CSN inhibits deneddylated SCF by a non-catalytic mechanism. *J. Biol. Chem.* 287, 29679-29689.
124. Oh, Y., Chang, K.J., Orlean, P., Wloka, C., Deshaies, R., and Bi, E. (2012). Mitotic exit kinase Dbf2 directly phosphorylates chitin synthase Chs2 to regulate cytokinesis in budding yeast. *Mol. Biol. Cell.* 23, 2445-2456.
125. Chou, T.F., Li, K., Frankowski, K.J., Schoenen, F.J., and Deshaies, R.J. (2013). Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. *Chem. Med. Chem.* 8, 297-312.
126. Verma, R., Oania, R.S., Kolawa, N.J., and Deshaies, R.J. (2013). Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. *Elife* 2, e00308.
127. Pierce, N.W., Lee, J.E., Liu, X., Sweredoski, M.J., Graham, R.L., Larimore, E.A., Rome, M., Zheng, N., Clurman, B.E., Hess, S., Shan, S.O., and Deshaies, R.J. (2013). Cnd1 promotes assembly of new SCF complexes through dynamic exchange of F box proteins. *Cell* 153, 206-215.
128. Chou, T.F., Li, K., Nordin, B.E., Porubsky, P., Frankowski, K., Patricelli, M.P., Aubé, J., Schoenen, F.J., and Deshaies, R. (2013). Selective, reversible inhibitors of the AAA ATPase p97. Probe Reports from the NIH Molecular Libraries Program [Internet], National Center for Biotechnology Information, 2010-April 14, 2011 (updated May 1, 2013).

129. Kurimchak, A., Haines, D.S., Garriga, J., Wu, S., De Luca, F., Sweredoski, M.J., Deshaies, R.J., Hess, S., and Graña, A. (2013). Activation of p107 by FGF, which is essential for chondrocyte cell cycle exit, is mediated by the PP2A/B55a holoenzyme. *Mol. Cell. Biol.* 33, 3330-3342.
130. Kolawa, N.J., Sweredoski, M.J., Graham, R.L.J., Oania, R., Hess, S., and Deshaies, R.J. (2013). Perturbations to the ubiquitin conjugate proteome in yeast *Dubx* mutants identify *Ubx2* as a regulator of membrane lipid composition. *Mol. Cell. Proteomics* 12, 2791-2803.
131. Radhakrishnan, S.K., den Besten, W. and Deshaies, R.J. (2014). p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. *eLife* 3, e01856.
132. Honarpour, N., Rose, C.M., Brumbaugh, J., Anderson, J., Graham, R.L., Sweredoski, M.J., Hess, S., Coom, J.J. and Deshaies, R.J. (2014). FBXL16 binds PP2A and regulates differentiation of embryonic stem cells along the FLK1+ lineage. *Mol. Cell. Proteomics* 13, 780-791.
133. Chou, T.F., Bulfer, S.L., Wehl, C.C., Li, K., Lis, L.G., Walters, M.A., Schoenen, F.J., Lin, H.J., Deshaies, R.J., and Arkin, M.R. (2014). Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains. *J. Mol. Biol.* 426, 2886-2899.
134. Chan, N.C., den Besten, W., Sweredoski, M.J., Hess, S., Deshaies, R.J., and Chan, D.C. (2014). Degradation of the deubiquitinating enzyme USP33 is mediated by p97 and the ubiquitin ligase HERC2. *J. Biol. Chem.* 289, 19789-19799.
135. Deshaies, R.J. (2014). Structural biology: Corraling a protein-degradation regulator. *Nature* 512, 145-146.
136. Fang, N.N., Chan, G.T., Zhu, M., Comyn, S.A., Persaud, A., Deshaies, R.J., Rotin, D., Gsponer, J., Mayor, T. (2014). Rsp5/Nedd4 is the main ubiquitin ligase that targets cytosolic misfolded proteins following heat stress. *Nat. Cell Biol.* 16, 1227-1237.
137. Deshaies, R.J. (2014). Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. *BMC Biol.* 12:94.
138. Pulvino, M., Chen, L., Oleksyn, D., Li, J., Compitello, G., Rossi, R., Spence, S., Balakrishnan, V., Jordan, C., Poligone, B., Casulo, C., Burack, R., Shapiro, J.L., Bernstein, S., Friedberg, J.W., Deshaies, R.J., Land, H., and Zhao, J. (2015). Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. *Oncotarget* 6, 14796-14813.
139. Deshaies, R.J. (2015). Protein degradation: Prime time for PROTACs. *Nat. Chem. Biol.* 11, 634-635.
140. Alvarez, C., Bulfer, S.L., Chakrasali, R., Chimenti, M.S., Deshaies R.J., Green, N., Kelly, M., LaPorte, M.G., Lewis, T.S., Liang, M., Moore, W.J., Neitz, R.J., Peshkov, V.A., Walters, M.A., Zhang, F., Arkin, M.R., Wipf, P., Huryn, D.M. (2016). Allosteric indoleamide inhibitors of p97: Identification of a novel probe of the ubiquitin pathway. *ACS Med. Chem. Lett.* 2, 182-187.

141. Banerjee, S., Bartesaghi, A., Merk, A., Prashant, R., Bulfer, S. L., Yan, Y., Green, N., Mroczkowski, B., Neitz, R.J., Wipf, P., Falconieri, V., Deshaies, R.J., Milne, J.L.S., Huryn, D., Arkin, M., Subramaniam, S. (2016). 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. *Science* 351, 871-875.
142. Nguyen, T.V., Lee, J.E., Sweredoski, M.J., Yang, S.J., Jeon, S.J., Harrison, J.S., Yim, J.H., Lee, S.G., Handa, H., Kuhlman, B., Jeong, J.S., Reitsma, J.M., Park, C.S., Hess, S., Deshaies, R.J. (2016). Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. *Mol. Cell* 6, 809-820.
143. Mosadeghi, R., Reichermeier, K.M., Winkler, M., Schreiber, A., Reitsma, J.M., Zhang, Y., Stengel, F., Cao, J., Kim, M., Sweredoski, M.J., Hess, S., Leitner, A., Aebersold, R., Peter, M., Deshaies, R.J., Enchev, R.I. (2016). Structural and kinetic analysis of the COP9-Signalosome activation and the cullin-RING ubiquitin ligase deneddylation cycle. *eLife* 5, e12102.
144. Sung, M.K., Reitsma, J.M., Sweredoski, M.J., Hess, S., Deshaies, R.J. (2016). Ribosomal proteins produced in excess are degraded by the ubiquitin-proteasome system. *Mol. Biol. Cell* 27, 2642-2652.
145. Xue, L., Blythe, E.E., Freiberger, E.C., Mamrosh, J., Hebert, A.S., Reitsma, J.M., Hess, S., Coon, J.J., Deshaies, R.J. (2016). VCP-adaptor interactions are exceptionally dynamic and subject to differential modulation by a VCP inhibitor. *Mol. Cell. Proteomics* 15, 2970-2986.
146. Sung, M.K., Porras-Yakushi, T.R., Reitsma, J.M., Huber, F.M., Sweredoski, M.J., Hoelz, A., Hess, S., Deshaies, R.J. (2016). A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins. *eLife* 5, 19105.
147. Kleiger, G. and Deshaies, R. (2016). Tag Team Ubiquitin Ligases. *Cell* 166, 1080-1081.
148. Vangala, J.R., Sotzny, F., Kruger, E., Deshaies, R.J., Radhakrishnan, S.K. (2016). Nrf1 can be processed and activated in a proteasome-independent manner. *Curr. Biol.* 26, R834-835.
149. Reiterer, V., Figueras-Puig C., Le Guerroue F., Confalonieri, S., Vecchi, M., Jalapothu, D., Kanse, S.M., Deshaies, R.J., Di Fiore, P.P., Behrends, C., Farhan, H. (2016). The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function. *EMBO J.*, 3, 260-273.
150. Perez, C., Li, J., Parlati, F., Rouffet, M., Ma, Y., Mackinnon, A.L., Chou, T.F., Deshaies, R.J. and Cohen, S.M. (2017). Discovery of an Inhibitor of the Proteasome Subunit Rpm11. *J. Med. Chem.* 4, 1343-1361. Correction: *J. Med. Chem.* 7, 3217.
151. Li, J., Yakushi, T., Parlati, F., Mackinnon, A.L., Perez, C., Ma, Y., Carter, K.P., Colayco, S., Magnuson, G., Brown, B., Nguyen, K., Vasile, S., Suyama, E., Smith, L.H., Sergienko, E., Pinkerton, A.B., Chung, T.D., Palmer, A.E., Pass, I., Hess, S., Cohen, S.M., and Deshaies R.J. (2017). Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. *Nat. Chem. Biol.* 5, 486-493.
152. Nguyen, T.V., Li, J., Lu, C.J., Mamrosh, J.L., Lu, G., Cathers, B.E., and Deshaies, R.J. (2017). P97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. *Proc. Natl. Acad. Sci. U S A* 14, 3565-3571.

153. Lauinger, L., Li, J., Shostak, A., Cemel, I.A., Ha, N., Zhang, Y., Merkl, P.E., Obermeyer, S., Stankovic-Valentin, N., Schafmeier, T., Wever, W.J., Bowers, A.A., Carter, K.P., Palmer, A.E., Tschochner, H., Melchior, F., Deshaies, R.J., Brunner, M., and Diernfellner, A. (2017). Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases. *Nat. Chem. Biol.* E-published ahead of print May 1, 2017.
154. Blythe, E.E., Olson, K.C., Chau, V. and Deshaies, R.J. (2017). Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy. *Proc. Natl. Acad. Sci. U S A.* E-published ahead of print May 16, 2017.